{"id":51764,"date":"2025-12-22T18:43:59","date_gmt":"2025-12-22T10:43:59","guid":{"rendered":"https:\/\/flcube.com\/?p=51764"},"modified":"2025-12-22T18:44:00","modified_gmt":"2025-12-22T10:44:00","slug":"gsks-nucala-wins-china-approval-as-first-il-5-biologic-for-copd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51764","title":{"rendered":"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) China<\/strong> announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> approved <strong>Nucala (mepolizumab injection)<\/strong> as an <strong>add\u2011on maintenance treatment<\/strong> for adult patients with <strong>inadequately controlled chronic obstructive pulmonary disease (COPD)<\/strong> characterized by an eosinophilic phenotype. This marks the <strong>first IL\u20115 biologic<\/strong> approved for COPD in China, supported by positive <strong>Phase\u202fIII MATINEE and METREX trials<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Approval Date<\/strong><\/td><td>22\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Nucala (mepolizumab injection)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Add\u2011on maintenance for eosinophilic COPD in adults<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Humanized anti\u2011IL\u20115 monoclonal antibody; inhibits eosinophil development\/maturation\/activation<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td><strong>First IL\u20115 biologic<\/strong> approved in China for COPD<\/td><\/tr><tr><td><strong>Supporting Trials<\/strong><\/td><td>Phase\u202fIII MATINEE and METREX<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Key Efficacy<\/th><th>Safety Profile<\/th><\/tr><\/thead><tbody><tr><td><strong>MATINEE<\/strong><\/td><td>Significant reduction in annual rate of moderate\u2011to\u2011severe exacerbations vs. placebo<\/td><td>Adverse event incidence similar to placebo<\/td><\/tr><tr><td><strong>METREX<\/strong><\/td><td>Clinically meaningful exacerbation reduction across broad eosinophilic COPD population<\/td><td>Comparable safety to placebo<\/td><\/tr><tr><td><strong>Combined Result<\/strong><\/td><td>Consistent efficacy in reducing COPD exacerbations<\/td><td>Well\u2011tolerated with standard of care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<p><strong>Nucala\u2019s China Portfolio:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Severe eosinophilic asthma (SEA)<\/strong> \u2013 adults &amp; adolescents \u226512\u202fyears<\/li>\n\n\n\n<li><strong>Chronic rhinosinusitis with nasal polyps (CRSwNP)<\/strong> \u2013 adults<\/li>\n\n\n\n<li><strong>Eosinophilic granulomatosis with polyangiitis (EGPA)<\/strong> \u2013 adults<\/li>\n\n\n\n<li><strong>COPD<\/strong> \u2013 adults (newly approved)<\/li>\n<\/ul>\n\n\n\n<p><strong>Global Status:<\/strong> Already approved for COPD in the United States.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><th>Context<\/th><\/tr><\/thead><tbody><tr><td><strong>China COPD Patients<\/strong><\/td><td><strong>100\u202fmillion<\/strong> (2025)<\/td><td>~10\u201115% have eosinophilic phenotype (10\u201115\u202fM eligible)<\/td><\/tr><tr><td><strong>China COPD Market<\/strong><\/td><td><strong>\u00a580\u2011100\u202fbillion<\/strong> (\u2248\u202fUS$11\u201114\u202fB)<\/td><td>Dominated by bronchodilators and inhaled steroids<\/td><\/tr><tr><td><strong>Biologic Penetration<\/strong><\/td><td>&lt;5% of eligible patients receive biologics<\/td><td>High growth potential with targeted therapies<\/td><\/tr><tr><td><strong>Nucala Peak Sales<\/strong><\/td><td><strong>\u00a52\u20113\u202fbillion<\/strong> (\u2248\u202fUS$280\u2011420\u202fM) by 2030<\/td><td>15\u201120% share of eosinophilic COPD segment<\/td><\/tr><tr><td><strong>Pricing Strategy<\/strong><\/td><td>Premium biologic pricing<\/td><td>Potential for NRDL inclusion by 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For GSK:<\/strong> <strong>COPD approval<\/strong> strengthens respiratory franchise in China; <strong>first IL\u20115 biologic<\/strong> creates competitive moat; builds on <strong>US approval<\/strong> for global consistency; addresses high\u2011unmet\u2011need eosinophilic phenotype.<\/li>\n\n\n\n<li><strong>For Patients:<\/strong> <strong>Add\u2011on therapy<\/strong> reduces exacerbation risk vs. standard of care; <strong>subcutaneous injection<\/strong> every 4\u20116 weeks offers convenience; <strong>targeted mechanism<\/strong> minimizes systemic steroid exposure.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> <strong>IL\u20115 inhibition<\/strong> expands beyond asthma into <strong>COPD<\/strong>, a larger patient population; <strong>MATINEE\/METREX data<\/strong> supports payer acceptance; <strong>GSK\u2019s respiratory leadership<\/strong> reinforced with differentiated biologic.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Nucala\u2019s market penetration, NRDL negotiations, and competitive positioning. Actual results may differ due to payer access, competitive responses, or safety profile changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline (GSK, NYSE: GSK) China announced that China\u2019s National Medical Products Administration (NMPA) approved Nucala&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51765,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,914,15],"class_list":["post-51764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline (GSK, NYSE: GSK) China announced that China\u2019s National Medical Products Administration (NMPA) approved Nucala (mepolizumab injection) as an add\u2011on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This marks the first IL\u20115 biologic approved for COPD in China, supported by positive Phase\u202fIII MATINEE and METREX trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51764\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline (GSK, NYSE: GSK) China announced that China\u2019s National Medical Products Administration (NMPA) approved Nucala (mepolizumab injection) as an add\u2011on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This marks the first IL\u20115 biologic approved for COPD in China, supported by positive Phase\u202fIII MATINEE and METREX trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51764\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T10:43:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-22T10:44:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD\",\"datePublished\":\"2025-12-22T10:43:59+00:00\",\"dateModified\":\"2025-12-22T10:44:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764\"},\"wordCount\":397,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2201.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51764#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51764\",\"name\":\"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2201.webp\",\"datePublished\":\"2025-12-22T10:43:59+00:00\",\"dateModified\":\"2025-12-22T10:44:00+00:00\",\"description\":\"GlaxoSmithKline (GSK, NYSE: GSK) China announced that China\u2019s National Medical Products Administration (NMPA) approved Nucala (mepolizumab injection) as an add\u2011on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This marks the first IL\u20115 biologic approved for COPD in China, supported by positive Phase\u202fIII MATINEE and METREX trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51764\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2201.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51764#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline (GSK, NYSE: GSK) China announced that China\u2019s National Medical Products Administration (NMPA) approved Nucala (mepolizumab injection) as an add\u2011on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This marks the first IL\u20115 biologic approved for COPD in China, supported by positive Phase\u202fIII MATINEE and METREX trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51764","og_locale":"en_US","og_type":"article","og_title":"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD","og_description":"GlaxoSmithKline (GSK, NYSE: GSK) China announced that China\u2019s National Medical Products Administration (NMPA) approved Nucala (mepolizumab injection) as an add\u2011on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This marks the first IL\u20115 biologic approved for COPD in China, supported by positive Phase\u202fIII MATINEE and METREX trials.","og_url":"https:\/\/flcube.com\/?p=51764","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-22T10:43:59+00:00","article_modified_time":"2025-12-22T10:44:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51764#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51764"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD","datePublished":"2025-12-22T10:43:59+00:00","dateModified":"2025-12-22T10:44:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51764"},"wordCount":397,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51764#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2201.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51764#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51764","url":"https:\/\/flcube.com\/?p=51764","name":"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51764#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51764#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2201.webp","datePublished":"2025-12-22T10:43:59+00:00","dateModified":"2025-12-22T10:44:00+00:00","description":"GlaxoSmithKline (GSK, NYSE: GSK) China announced that China\u2019s National Medical Products Administration (NMPA) approved Nucala (mepolizumab injection) as an add\u2011on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This marks the first IL\u20115 biologic approved for COPD in China, supported by positive Phase\u202fIII MATINEE and METREX trials.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51764#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51764"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51764#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2201.webp","width":1080,"height":608,"caption":"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51764#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK\u2019s Nucala Wins China Approval as First IL\u20115 Biologic for COPD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51764"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51764\/revisions"}],"predecessor-version":[{"id":51766,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51764\/revisions\/51766"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51765"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}